Karuna Therapeutics Inc. (KRTX) PT Raised to $260 at Stifel

August 8, 2022 3:59 PM EDT
Get Alerts KRTX Hot Sheet
Price: $226.94 +0.89%

Rating Summary:
    16 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 6 | Down: 13 | New: 11
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Paul Matteis raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $260.00 (from $185.00) while maintaining a Buy rating.

The analyst comments "We rate KRTX shares Buy. Karuna is a biotechnology company focused on the development of novel neuroscience drugs. Our thesis on the stock centers on our bullish view on lead asset KarXT, a novel muscarinic agonist/peripheral antagonist combo-product that recently succeeded in a ph3 trial in schizophrenia. KarXT follows a long history of scientific research regarding the muscarinic receptor system in psychosis and cognition, and represents a solution to previous side effect challenges that limited the therapeutic index of first generation molecules. Neuropsychiatry drug development is tough. We believe KarXT could become a multi-billion dollar schizophrenia product, based on KOL feedback suggesting that the drug, as a novel MOA, could be a go-to medicine in the currently large non-responder population. Finally, KarXT also has the potential to be a "pipeline-in-a-product", as Karuna plans on exploring the drug in dementia-related psychosis as well as pain. While riskier, with proof-of-concept data in the elderly, we view DRP as more de-risked while there remains additional potential for upside in pain if Karuna can demonstrate evidence of analgesic benefit in a proof-of-concept setting."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities